Analyst firms · Morgan Stanley · GH

Morgan Stanley GH price target and rating history

Guardant Health Inc. (GH) · Health Care

Morgan Stanley rates Guardant Health Inc. (GH) Overweight with a $130 price target, as of its latest action on Dec 2, 2025. It has published 3 rating actions on GH since February 2022, including 0 upgrades and 0 downgrades. Across 11 firms with a GH price target in the last 12 months, the median target is $165. Morgan Stanley's $130 is 21% below that.

Current rating
Overweight
Price target
$130
Median target, all firms
$165
Actions on GH
3

Morgan Stanley price target on GH

$130$125$1202023202420252026
Morgan Stanley price target on GH, each point a stated target, February 2022 to December 2025.

Every Morgan Stanley rating on GH

How other firms rate GH

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Roth CapitalBuy$200Oct 23, 2026
UBSBuy$225Sep 9, 2026
Rothschild & Co RedburnBuy$203Sep 8, 2026
BernsteinOutperform$175Jun 26, 2026
RBC Capital MarketsOutperform$185Jun 12, 2026
Goldman SachsBuy$165Jun 5, 2026
Wolfe ResearchOutperform$150Jun 2, 2026
Evercore ISIOutperform$160Jun 2, 2026
Canaccord GenuityBuy$135Feb 20, 2026
Robert W. BairdOutperform$120Feb 17, 2026
Morgan StanleyOverweight$130Dec 2, 2025

Questions about Morgan Stanley and GH

What is Morgan Stanley's price target for GH?
Morgan Stanley's latest stated price target for Guardant Health Inc. (GH) is $130, from its action on Dec 2, 2025.
What is Morgan Stanley's rating on GH?
Morgan Stanley rates GH Overweight, a bullish rating, as of Dec 2, 2025.
When did Morgan Stanley last change its view on GH?
On Dec 2, 2025, Morgan Stanley resumes coverage at Overweight, price target $130.
How does Morgan Stanley's GH target compare with other analysts?
Across 11 firms with a GH price target in the last 12 months, the median target is $165. Morgan Stanley's $130 is 21% below that.

More GH rating histories

All Morgan Stanley ratingsGH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.